AU
UK
CA
US
IND
NZ
Last update at 2026-06-03T20:10:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?
Mon 26 May 25, 01:40 PMBristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting
Fri 23 May 25, 05:21 PMEXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
Fri 23 May 25, 01:57 PMBranded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)
Thu 22 May 25, 03:31 AMHere's How You Can Earn $100 In Passive Income By Investing In Bristol-Myers Squibb Stock
Tue 20 May 25, 12:01 PM1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About
Tue 20 May 25, 04:33 AMAmgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
Mon 19 May 25, 05:29 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 9328.00M | -8379.00000M | 8440.00M | 7713.00M | 8098.00M |
| Minority interest | -2.00000M | -15.00000M | -18.00000M | -18.00000M | -20.00000M |
| Net income | 7053.00M | -8948.00000M | 8025.00M | 6327.00M | 6994.00M |
| Selling general administrative | 5660.00M | 6365.00M | 6278.00M | 7808.00M | 7688.00M |
| Selling and marketing expenses | 1584.00M | 1500.00M | 1400.00M | 7814.00M | 7690.00M |
| Gross profit | 32602.00M | 27432.00M | 25357.00M | 36022.00M | 36445.00M |
| Reconciled depreciation | 4011.00M | 9600.00M | 9817.00M | 9595.00M | 10023.00M |
| Ebit | 10685.00M | -6432.00000M | 9606.00M | 10328.00M | 10159.00M |
| Ebitda | 14545.00M | 3168.00M | 19366.00M | 19923.00M | 20182.00M |
| Depreciation and amortization | 3860.00M | 9600.00M | 9760.00M | 9595.00M | 10023.00M |
| Non operating income net other | - | - | - | -576.00000M | 720.00M |
| Operating income | 12696.00M | 9658.00M | 8472.00M | 10328.00M | 10159.00M |
| Other operating expenses | 35498.00M | 38642.00M | 36534.00M | 37055.00M | 37848.00M |
| Interest expense | 1510.00M | 1947.00M | 1166.00M | 1232.00M | 1334.00M |
| Tax provision | 2272.00M | 554.00M | 322.00M | 1368.00M | 1084.00M |
| Interest income | 1025.00M | 1453.00M | 877.00M | 1862.00M | 550.00M |
| Net interest income | -1891.00000M | -1947.00000M | -1144.00000M | -1232.00000M | -1334.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 2272.00M | 554.00M | 400.00M | 1368.00M | 1084.00M |
| Total revenue | 48194.00M | 48300.00M | 45006.00M | 46159.00M | 46385.00M |
| Total operating expenses | 19906.00M | 17774.00M | 16885.00M | 26918.00M | 27908.00M |
| Cost of revenue | 15592.00M | 20868.00M | 19649.00M | 10137.00M | 9940.00M |
| Total other income expense net | -3368.00000M | -18037.00000M | -32.00000M | -2615.00000M | -2061.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 7055.00M | -8933.00000M | 8303.00M | 6345.00M | 7014.00M |
| Net income applicable to common shares | 7054.00M | -8948.00000M | 8025.00M | 6327.00M | 6994.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 90038.00M | 92603.00M | 95159.00M | 96820.00M | 109314.00M |
| Intangible assets | 19103.00M | 23643.00M | 27485.00M | 36355.00M | 42775.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1502.00M | 1940.00M | 1564.00M | 1596.00M | 1290.00M |
| Total liab | 71532.00M | 76215.00M | 65674.00M | 65702.00M | 73308.00M |
| Total stockholder equity | 18473.00M | 16335.00M | 29430.00M | 31061.00M | 35946.00M |
| Deferred long term liab | - | - | - | 2166.00M | 4501.00M |
| Other current liab | 16400.00M | 16431.00M | 14351.00M | 13106.00M | 10109.00M |
| Common stock | 292.00M | 292.00M | 292.00M | 292.00M | 292.00M |
| Capital stock | 292.00M | 292.00M | 292.00M | 292.00M | 292.00M |
| Retained earnings | 16896.00M | 14912.00M | 28766.00M | 25503.00M | 23820.00M |
| Other liab | - | - | - | 7392.00M | 10961.00M |
| Good will | 21754.00M | 21719.00M | 21169.00M | 21149.00M | 20502.00M |
| Other assets | 8174.00M | 7381.00M | 5049.00M | 2877.00M | 3342.00M |
| Cash | 10209.00M | 10346.00M | 11464.00M | 9123.00M | 13979.00M |
| Cash and equivalents | 10209.00M | 10346.00M | 11464.00M | 9123.00M | 13979.00M |
| Total current liabilities | 23417.00M | 23774.00M | 22262.00M | 21890.00M | 21868.00M |
| Current deferred revenue | - | - | 271.00M | 1344.00M | 3693.00M |
| Net debt | 36930.00M | 40854.00M | 30000.00M | 31594.00M | 31617.00M |
| Short term debt | 2463.00M | 2227.00M | 3281.00M | 4400.00M | 5117.00M |
| Short long term debt | 2261.00M | 2046.00M | 3119.00M | 4264.00M | 4948.00M |
| Short long term debt total | 47139.00M | 51200.00M | 41464.00M | 40717.00M | 45596.00M |
| Other stockholder equity | 2808.00M | 2369.00M | 1918.00M | 6547.00M | 13102.00M |
| Property plant equipment | 9125.00M | 8360.00M | 8036.00M | 6255.00M | 6049.00M |
| Total current assets | 29390.00M | 29780.00M | 31770.00M | 27273.00M | 33262.00M |
| Long term investments | 2507.00M | 2508.00M | 2063.00M | 2187.00M | 2713.00M |
| Net tangible assets | - | - | - | -25947.00000M | -28236.00000M |
| Short term investments | 464.00M | 513.00M | 816.00M | 130.00M | 3242.00M |
| Net receivables | 14525.00M | 14424.00M | 15264.00M | 13937.00M | 12516.00M |
| Long term debt | 42850.00M | 47603.00M | 36653.00M | 35056.00M | 39605.00M |
| Inventory | 2690.00M | 2557.00M | 2662.00M | 2339.00M | 2095.00M |
| Accounts payable | 3575.00M | 3602.00M | 3259.00M | 3040.00M | 2949.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 55.00M | 57.00M | 60.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1523.00000M | -1238.00000M | -1546.00000M | -1281.00000M | -1268.00000M |
| Additional paid in capital | - | - | 0.00000M | - | - |
| Common stock total equity | - | - | - | 292.00M | 292.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | 25503.00M | 23820.00M |
| Treasury stock | - | - | -43766.00000M | - | -31259.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2781.00M | 2357.00M | 1432.00M | 1037.00M | 1655.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 60648.00M | 62823.00M | 63389.00M | 69547.00M | 76052.00M |
| Capital lease obligations | 2028.00M | 1551.00M | 1692.00M | 1397.00M | 1043.00M |
| Long term debt total | 42850.00M | 47603.00M | 36653.00M | 35056.00M | 39605.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 52.00M | -21352.00000M | 264.00M | 3037.00M | 1297.00M |
| Change to liabilities | - | - | - | -887.00000M | 45.00M |
| Total cashflows from investing activities | -4132.00000M | -21352.00000M | -2295.00000M | -1062.00000M | -538.00000M |
| Net borrowings | -5175.00000M | 10096.00M | 456.00M | -5311.00000M | -6182.00000M |
| Total cash from financing activities | -10348.00000M | 5127.00M | -9416.00000M | -16962.00000M | -16224.00000M |
| Change to operating activities | - | - | - | -183.00000M | 606.00M |
| Net income | 7055.00M | -8933.00000M | 8040.00M | 6345.00M | 7014.00M |
| Change in cash | -137.00000M | -1172.00000M | 2194.00M | -4991.00000M | -657.00000M |
| Begin period cash flow | 10347.00M | 11519.00M | 9325.00M | 14316.00M | 14973.00M |
| End period cash flow | 10218.00M | 10347.00M | 11519.00M | 9325.00M | 14316.00M |
| Total cash from operating activities | 14156.00M | 15190.00M | 13860.00M | 13066.00M | 16207.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 4011.00M | 9600.00M | 9760.00M | 10276.00M | 10686.00M |
| Other cashflows from investing activities | -2821.00000M | 1099.00M | -1086.00000M | -2981.00000M | -862.00000M |
| Dividends paid | 5045.00M | 4863.00M | 4744.00M | 4634.00M | 4396.00M |
| Change to inventory | -184.00000M | -486.00000M | -751.00000M | -69.00000M | 13.00M |
| Change to account receivables | -295.00000M | 264.00M | -995.00000M | -663.00000M | -2117.00000M |
| Sale purchase of stock | 0.00000M | 0.00000M | -5155.00000M | -8001.00000M | -6287.00000M |
| Other cashflows from financing activities | -128.00000M | -106.00000M | 27.00M | 7104.00M | 641.00M |
| Change to netincome | - | - | - | -1078.00000M | -748.00000M |
| Capital expenditures | 1311.00M | 1248.00M | 1209.00M | 1118.00M | 973.00M |
| Change receivables | - | - | - | -663.00000M | -1054.00000M |
| Cash flows other operating | - | - | - | -858.00000M | 251.00M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -4958.00000M | -555.00000M |
| Change in working capital | -455.00000M | 810.00M | -1914.00000M | -2229.00000M | -1253.00000M |
| Stock based compensation | 553.00M | 507.00M | 518.00M | 457.00M | 583.00M |
| Other non cash items | 3957.00M | 15295.00M | 744.00M | 955.00M | 570.00M |
| Free cash flow | 12845.00M | 13942.00M | 12651.00M | 11948.00M | 15234.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company |
0.26 0.48% | 54.72 | 17.16 | 9.46 | 2.52 | 6.54 | 3.26 | 10.32 |
| LLY Eli Lilly and Company |
14.63 1.37% | 1078.78 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
0.35 0.16% | 223.24 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
1.73 0.80% | 217.13 | 86.32 | 14.33 | 5.89 | 50.46 | 7.04 | 24.44 |
| AZN AstraZeneca PLC |
-1.17 0.66% | 176.28 | 30.69 | 19.23 | 5.30 | 6.45 | 5.72 | 17.23 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Route 206 & Province Line Road, Princeton, NJ, United States, 08543
| Name | Title | Year Born |
|---|---|---|
| Dr. Giovanni Caforio M.D. | Chairman & CEO | 1965 |
| Mr. David V. Elkins | Exec. VP & CFO | 1968 |
| Ms. Sandra Leung Esq. | Exec. VP & Gen. Counsel | 1961 |
| Dr. Christopher S. Boerner | Exec. VP & Chief Commercialization Officer | 1971 |
| Mr. Rupert Vessey BCH, BM, DPHIL, M.A. | Exec. VP and Pres of Research & Early Devel. | 1965 |
| Mr. Greg Meyers | Exec. VP and Chief Digital & Technology Officer | 1973 |
| Mr. Timothy Power | VP & Head of Investor Relations | NA |
| Ms. Cari Gallman | Sr. VP & Chief Compliance and Ethics Officer | NA |
| Ms. Ann M. Powell Judge | Exec. VP & Chief HR Officer | 1966 |
| Mr. Jitendra Tyagi | Head of US Drug Makers - India | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...